Patents Assigned to Hanmi Pharm. Co., Ltd.
  • Long-acting conjugate of triple glucagon/GLP-1/GIP receptor agonist
    Patent number: 10400020
    Abstract: The present invention relates to a long-acting conjugate of a triple agonist having activities to all of glucagon, GLP-1, and GIP receptors and uses thereof.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: September 3, 2019
    Assignee: HANMI PHARM. CO., LTD.
    Inventors: Euh Lim Oh, Jong Suk Lee, Young Jin Park, Chang Ki Lim, Sung Youb Jung, Se Chang Kwon
  • Process for preparing thienopyrimidine compound and intermediates used therein
    Patent number: 10392403
    Abstract: The present invention relates to a novel method for preparing thienopyrimidine compound having an activity of selectively inhibiting tyrosine kinase, specifically the mutant epidermal growth factor receptor tyrosine kinase; and a novel intermediate used therein. According to the method of the present invention, the industrial mass-production of the compound of Formula 1, which is useful as a therapeutic agent for non-small cell lung cancer induced by the mutant epidermal growth factor receptor tyrosine kinase, can be implemented more conveniently and efficiently than the conventional technology.
    Type: Grant
    Filed: October 31, 2016
    Date of Patent: August 27, 2019
    Assignee: HANMI PHARM. CO., LTD.
    Inventors: Wook Jang, Young Ho Moon, Tae Hee Ha, Kwee Hyun Suh
  • ESOMEPRAZOLE-CONTAINING COMPLEX CAPSULE AND PREPARATION METHOD THEREFOR
    Publication number: 20190247316
    Abstract: Provided are a composite capsule and a method of preparing the composite capsule. The composite capsule includes a first dissolving part including a core, an inner coating layer on the core, and a first enteric coating layer on the inner coating layer, wherein core contains, as an active ingredient, esomeprazole or a pharmaceutically acceptable salt thereof. The composite capsule further includes a second dissolving part including a core, which contains, as an active ingredient, esomeprazole or a pharmaceutically acceptable salt thereof, an inner coating layer on the core, and a second enteric coating layer on the inner coating layer.
    Type: Application
    Filed: October 19, 2017
    Publication date: August 15, 2019
    Applicant: HANMI PHARM. CO., LTD.
    Inventors: Taek Kwan KWON, Seung Hun CHANG, Ho Taek IM, Yong ll KIM, Jae Hyun PARK, Jong Soo WOO
  • Triple glucagon/GLP-1/GIP receptor agonist
    Patent number: 10370426
    Abstract: The present invention relates to a triple agonist having activities to all of glucagon, GLP-1, and GIP receptors and uses thereof.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: August 6, 2019
    Assignee: HANMI PHARM. CO., LTD
    Inventors: Euh Lim Oh, Jong Suk Lee, Young Jin Park, Chang Ki Lim, Sung Youb Jung, Se Chang Kwon
  • TRIPLE GLUCAGON/GLP-1/GIP RECEPTOR AGONIST
    Publication number: 20190218269
    Abstract: A a triple agonist having activities to all of glucagon, GLP-1, and GIP receptors is disclosed. Uses of the triple agonist are disclosed.
    Type: Application
    Filed: March 29, 2019
    Publication date: July 18, 2019
    Applicant: HANMI PHARM. CO., LTD
    Inventors: Euh Lim OH, Jong Suk Lee, Young Jin Park, Chang Ki Lim, Sung Youb Jung, Se Chang Kwon
  • LONG-ACTING CONJUGATE OF TRIPLE GLUCAGON/GLP-1/GIP RECEPTOR AGONIST
    Publication number: 20190153060
    Abstract: A long-acting conjugate of a triple agonist which has activities to all of glucagon, GLP-1, and GIP receptors and uses thereof.
    Type: Application
    Filed: January 31, 2019
    Publication date: May 23, 2019
    Applicant: HANMI PHARM. CO., LTD.
    Inventors: Euh Lim OH, Jong Suk Lee, Young Jin Park, Chang Ki Lim, Sung Youb Jung, Se Chang Kwon
  • Pyrimidine compound and pharmaceutical use thereof
    Patent number: 10280154
    Abstract: Provided are a pyrimidine compound represented by Formula 1, a method of preparing the same, and a pharmaceutical use of the pyrimidine compound for the prevention or treatment of cancer.
    Type: Grant
    Filed: September 11, 2018
    Date of Patent: May 7, 2019
    Assignee: HANMI PHARM. CO., LTD.
    Inventors: Young Jin Ham, Seok Jong Kang, Jae Yul Choi, Seo Hee Kim, Tae Woo Kim, In Hwan Bae, Young Gil Ahn, Kwee Hyun Suh
  • Liquid formulation of long-lasting protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment
    Patent number: 10279041
    Abstract: The present invention relates to an albumin-free liquid formulation comprising a long-lasting oxyntomodulin conjugate in which an oxyntomodulin peptide comprising a derivative, variant, precursor or fragment of oxyntomodulin is linked to an immunoglobulin Fc region, which can increase the duration of physiological activity of the long-lasting oxyntomodulin conjugate and maintain the in vivo stability thereof for an extended period of time, as compared to native oxyntomodulin, as well as a method for preparing the liquid formulation. The liquid formulation comprises a buffer, a sugar alcohol and a nonionic surfactant and does not contain a human serum albumin and factors that are potentially harmful to the human body, and thus is not susceptible to viral infection.
    Type: Grant
    Filed: June 29, 2017
    Date of Patent: May 7, 2019
    Assignee: Hanmi Pharm Co. Ltd.
    Inventors: Hyun Uk Kim, Hyung Kyu Lim, Myung Hyun Jang, Sang Yun Kim, Sung Min Bae, Se Chang Kwon
  • PYRIMIDINE COMPOUND AND PHARMACEUTICAL USE THEREOF
    Publication number: 20190127353
    Abstract: Provided are a pyrimidine compound represented by Formula 1, a method of preparing the same, and a pharmaceutical use of the pyrimidine compound for the prevention or treatment of cancer.
    Type: Application
    Filed: December 19, 2018
    Publication date: May 2, 2019
    Applicant: HANMI PHARM. CO., LTD.
    Inventors: Young Jin HAM, Seok Jong Kang, Jae Yul Choi, Seo Hee Kim, Tae Woo Kim, In Hwan Bae, Young Gil Ahn, Kwee Hyun Suh
  • COMPOSITE CAPSULE PREPARATION CONTAINING TADALAFIL AND TAMSULOSIN AND HAVING IMPROVED STABILITY AND ELUTION RATE
    Publication number: 20190125685
    Abstract: One aspect of the present invention provides: a composite capsule preparation containing tadalafil or a pharmaceutically acceptable salt thereof and tamsulosin or a pharmaceutically acceptable salt thereof, wherein the composite capsule preparation comprises, on the surface thereof, a film coating layer comprising, as a film coating material, polyvinyl alcohol (PVA) or a copolymer comprising PVA; and a preparation method therefor.
    Type: Application
    Filed: March 31, 2017
    Publication date: May 2, 2019
    Applicant: HANMI PHARM. CO., LTD.
    Inventors: Jin Wook TAK, Jung Hyun CHO, Jin Cheul KIM, Yong Il KIM, Jae Hyun PARK, Jong Soo WOO
  • GLUCAGON DERIVATIVE, CONJUGATE THEREOF, COMPOSITION COMPRISING SAME, AND THERAPEUTIC USE THEREOF
    Publication number: 20190119347
    Abstract: The present invention relates to a glucagon derivative, a conjugate thereof, and a composition comprising the same, and a therapeutic use thereof, and in particular, for metabolic syndrome, hypoglycemia, and congenital hyperinsulinism.
    Type: Application
    Filed: December 27, 2018
    Publication date: April 25, 2019
    Applicant: HANMI PHARM. CO., LTD
    Inventors: Jung Kuk KIM, Young Jin Park, In Young Choi, Sung Youb Jung
  • Long-acting insulin and use thereof
    Patent number: 10253082
    Abstract: The present invention relates to an insulin analog that has reduced insulin receptor binding affinity for the purpose of increasing the blood half-life of insulin, and long-acting insulin, a conjugate, and a method of preparing long-acting insulin using the same.
    Type: Grant
    Filed: January 20, 2015
    Date of Patent: April 9, 2019
    Assignee: HANMI PHARM. CO., LTD
    Inventors: Sung Youb Jung, Sang Youn Hwang, Euh Lim Oh, Sung Hee Park, Hyun Uk Kim, Chang Ki Lim, Se Chang Kwon
  • Use of a long acting GLP-1/glucagon receptor dual agonist for the treatment of non-alcoholic fatty liver disease
    Patent number: 10233230
    Abstract: The present invention relates to a pharmaceutical composition for the prevention or treatment of non-alcoholic fatty liver disease including a long-acting GLP-1/glucagon receptor dual agonist, and a method for preventing or treatment of non-alcoholic fatty liver disease including administering the composition. The composition of the present invention either has no side effect of weight gain or reduces the side effect of weight gain, which is a side-effect of conventional therapeutic agents for non-alcoholic fatty liver disease, and reduces the amount of administrations of a long-acting GLP-1/glucagon receptor dual agonist, thus greatly improving patient's convenience. In addition, the long-acting GLP-1/glucagon receptor dual agonist of the present invention improves in vivo sustainability and stability.
    Type: Grant
    Filed: September 16, 2015
    Date of Patent: March 19, 2019
    Assignee: Hanmi Pharm. Co., Ltd.
    Inventors: Sang Youn Hwang, Jin Young Kim, Seung Su Kim, In Young Choi, Sung Youb Jung, Se Chang Kwon
  • POLYETHYLENE GLYCOL DERIVATIVE AND USE THEREOF
    Publication number: 20190071379
    Abstract: The present invention relates to polyethylene glycol derivatives and use thereof.
    Type: Application
    Filed: March 7, 2017
    Publication date: March 7, 2019
    Applicant: HANMI PHARM. CO., LTD.
    Inventors: Dae Jin KIM, Jong Soo LEE, Sung Min BAE, Se Chang KWON
  • CONJUGATE OF THERAPEUTIC ENZYMES
    Publication number: 20190046657
    Abstract: The present invention relates to a conjugate in which an immunoglobulin Fc region is linked to therapeutic enzymes through a non-peptide polymer linkage moiety, and more specifically, to a conjugate in which a non-peptide polymer linkage moiety is specifically linked to an immunoglobulin Fc, a method of preparing the same, and a composition comprising the same.
    Type: Application
    Filed: January 31, 2017
    Publication date: February 14, 2019
    Applicant: HANMI PHARM. CO., LTD.
    Inventors: Dae Jin KIM, Jung Kuk KIM, Sung Youb JUNG, Se Chang KWON
  • PYRIMIDINE COMPOUND AND PHARMACEUTICAL USE THEREOF
    Publication number: 20190031643
    Abstract: Provided are a pyrimidine compound represented by Formula 1, a method of preparing the same, and a pharmaceutical use of the pyrimidine compound for the prevention or treatment of cancer.
    Type: Application
    Filed: September 11, 2018
    Publication date: January 31, 2019
    Applicant: HANMI PHARM. CO., LTD.
    Inventors: Young Jin HAM, Seok Jong KANG, Jae Yul CHOI, Seo Hee KIM, Tae Woo KIM, In Hwan BAE, Young Gil AHN, Kwee Hyun SUH
  • Method for treating diabetes mellitus by a composition comprising insulin and a GLP-1/glucagon dual agonist
    Patent number: 10188703
    Abstract: A composition for preventing or treating diabetes mellitus includes insulin and a GLP-1/glucagon dual agonist. The composition can inhibit the weight gain and reduce the danger of hypoglycemia due to the administration of insulin, lower the administration dose and greatly improve the compliance of drugs through a combined administration of a long-acting insulin conjugate and a long-acting GLP-1/glucagon dual agonist conjugate. In addition, the long-acting insulin conjugate and the long-acting GLP-1/glucagon dual agonist conjugate can improve the in vivo sustainability and stability because an insulin and a GLP-1/glucagon dual agonist are linked to the immunoglobulin Fc region via a non-peptidyl linker. A method for preventing or treat diabetes mellitus includes administration of the insulin and a GLP-1/glucagon dual agonist.
    Type: Grant
    Filed: June 1, 2015
    Date of Patent: January 29, 2019
    Assignee: HANMI PHARM. CO., LTD.
    Inventors: Sung Youb Jung, Sang Youn Hwang, Seung Su Kim, In Young Choi, Se Chang Kwon
  • A NOVEL LIQUID FORMULATION OF LONG-ACTING HUMAN GROWTH HORMONE CONJUGATE
    Publication number: 20190022183
    Abstract: The present invention relates to a liquid formulation of a long-acting human growth hormone conjugate and a preparation method thereof.
    Type: Application
    Filed: December 30, 2016
    Publication date: January 24, 2019
    Applicant: HANMI PHARM. CO., LTD.
    Inventors: Hyung Kyu LIM, Joo Young DONG, Sung Min BAE, Se Chang KWON
  • CRYSTALLINE FORMS OF THIENOPYRIMIDINE COMPOUND
    Publication number: 20190016733
    Abstract: The present invention relates to crystalline forms of N-(3-(2-(4-(4-methylpiperazin-1-yl)phenylamino)thieno[3,2-d]pyrimidin-4-yloxy)phenyl)acrylamide, and pharmaceutical compositions containing the same. The crystalline forms can be easily used for the preparation of a pharmaceutical composition containing the same as an active ingredient.
    Type: Application
    Filed: December 30, 2016
    Publication date: January 17, 2019
    Applicant: HANMI PHARM. CO., LTD.
    Inventors: Jae Hyuk JUNG, Jong Ouk BAEK, Sun Young JUNG, Eun Joo KWAK, Hee Cheol KIM, Tae Hee HA
  • Thieno[3,2-D]pyrimidine derivatives having inhibitory activity for protein kinases
    Patent number: RE47451
    Abstract: Provided are a thieno[3,2-d]pyrimidine derivative of formula (I) or a pharmaceutically acceptable salt thereof having inhibitory activity for protein kinase, and a pharmaceutical composition comprising same for prevention and treatment of abnormal cell growth diseases.
    Type: Grant
    Filed: October 13, 2017
    Date of Patent: June 25, 2019
    Assignee: Hanmi Pharm. Co. Ltd.
    Inventors: In Hwan Bae, Jung Beom Son, Sang Mi Han, Eun Joo Kwak, Ho Seok Kim, Ji Young Song, Eun Young Byun, Seung Ah Jun, Young Gil Ahn, Kwee Hyun Suh